Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome

Bruce A. Buehler, Duane Delimont, Michael Van Waes, Richard H. Finnell

Research output: Contribution to journalArticle

200 Citations (Scopus)

Abstract

The well-known teratogenicity of several anticonvulsant medications is associated with an elevated level of oxidative metabolites that are normally eliminated by the enzyme epoxide hydrolase. In this study, we attempted to determine whether infants who are at risk for congenital malformations could be identified prenatally by the measurement of epoxide hydrolase activity. Before fetuses at risk could be identified, it was necessary to measure epoxide hydrolase activity in a randomly selected sample of amniocytes from 100 pregnant women. According to a thin-layer Chromatographic ssay, the randomly selected sample population had an apparently trimodal distribution, suggestive of an enzyme regulated by a single gene with two allelic forms. Fetuses homozygous for the recessive allele would have low epoxide hydrolase activity and would therefore be at risk if exposed to anticonvulsant drugs during gestation. In a prospective study of 19 pregnancies monitored by amniocentesis, an adverse outcome was predicted for four fetuses on the basis of low enzyme activity (<30 percent of the standard). In all four cases, the mother was receiving phenytoin monotherapy, and after birth the infants had clinical findings compatible with the fetal hydantoin syndrome. The 15 fetuses with enzyme activity above 30 percent of the standard were not considered to be at risk, and all 15 neonates lacked any characteristic features of the fetal hydantoin syndrome. These preliminary results suggest that this enzymatic biomarker may prove useful in determining which infants are at increased risk for congenital malformations induced by anticonvulsant drugs. THE association among maternal epilepsy, anticonvulsant drugs, and an increased incidence of congenital abnormalities has been suspected for at least 25 years.1 Despite numerous clinical and epidemiologic studies in humans that have documented well over 5000 births complicated by maternal epilepsy,2,3 only trimethadione,4 phenytoin,5,6 and valproic acid7 8 9 10 are widely considered to be human teratogens. Although all the commonly available anticonvulsant medications have at least been implicated as potential teratogens, recent attention has been focused on phenytoin, valproic acid, carbamazepine, and combination therapy with these three compounds.11 12 13 In terms of clinical understanding, the fetal hydantoin (phenytoin) syndrome is by far the…

Original languageEnglish (US)
Pages (from-to)1567-1572
Number of pages6
JournalNew England Journal of Medicine
Volume322
Issue number22
DOIs
StatePublished - May 31 1990

Fingerprint

Epoxide Hydrolases
Anticonvulsants
Phenytoin
Fetus
Teratogens
Mothers
Enzymes
Epilepsy
Trimethadione
Parturition
Pregnancy
Amniocentesis
Carbamazepine
Valproic Acid
Pregnant Women
Epidemiologic Studies
Biomarkers
Alleles
Fetal hydantoin syndrome
Newborn Infant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Buehler, B. A., Delimont, D., Van Waes, M., & Finnell, R. H. (1990). Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome. New England Journal of Medicine, 322(22), 1567-1572. https://doi.org/10.1056/NEJM199005313222204

Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome. / Buehler, Bruce A.; Delimont, Duane; Van Waes, Michael; Finnell, Richard H.

In: New England Journal of Medicine, Vol. 322, No. 22, 31.05.1990, p. 1567-1572.

Research output: Contribution to journalArticle

Buehler, BA, Delimont, D, Van Waes, M & Finnell, RH 1990, 'Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome', New England Journal of Medicine, vol. 322, no. 22, pp. 1567-1572. https://doi.org/10.1056/NEJM199005313222204
Buehler, Bruce A. ; Delimont, Duane ; Van Waes, Michael ; Finnell, Richard H. / Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome. In: New England Journal of Medicine. 1990 ; Vol. 322, No. 22. pp. 1567-1572.
@article{d652492f3ee84a4d824f93cb6412b961,
title = "Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome",
abstract = "The well-known teratogenicity of several anticonvulsant medications is associated with an elevated level of oxidative metabolites that are normally eliminated by the enzyme epoxide hydrolase. In this study, we attempted to determine whether infants who are at risk for congenital malformations could be identified prenatally by the measurement of epoxide hydrolase activity. Before fetuses at risk could be identified, it was necessary to measure epoxide hydrolase activity in a randomly selected sample of amniocytes from 100 pregnant women. According to a thin-layer Chromatographic ssay, the randomly selected sample population had an apparently trimodal distribution, suggestive of an enzyme regulated by a single gene with two allelic forms. Fetuses homozygous for the recessive allele would have low epoxide hydrolase activity and would therefore be at risk if exposed to anticonvulsant drugs during gestation. In a prospective study of 19 pregnancies monitored by amniocentesis, an adverse outcome was predicted for four fetuses on the basis of low enzyme activity (<30 percent of the standard). In all four cases, the mother was receiving phenytoin monotherapy, and after birth the infants had clinical findings compatible with the fetal hydantoin syndrome. The 15 fetuses with enzyme activity above 30 percent of the standard were not considered to be at risk, and all 15 neonates lacked any characteristic features of the fetal hydantoin syndrome. These preliminary results suggest that this enzymatic biomarker may prove useful in determining which infants are at increased risk for congenital malformations induced by anticonvulsant drugs. THE association among maternal epilepsy, anticonvulsant drugs, and an increased incidence of congenital abnormalities has been suspected for at least 25 years.1 Despite numerous clinical and epidemiologic studies in humans that have documented well over 5000 births complicated by maternal epilepsy,2,3 only trimethadione,4 phenytoin,5,6 and valproic acid7 8 9 10 are widely considered to be human teratogens. Although all the commonly available anticonvulsant medications have at least been implicated as potential teratogens, recent attention has been focused on phenytoin, valproic acid, carbamazepine, and combination therapy with these three compounds.11 12 13 In terms of clinical understanding, the fetal hydantoin (phenytoin) syndrome is by far the…",
author = "Buehler, {Bruce A.} and Duane Delimont and {Van Waes}, Michael and Finnell, {Richard H.}",
year = "1990",
month = "5",
day = "31",
doi = "10.1056/NEJM199005313222204",
language = "English (US)",
volume = "322",
pages = "1567--1572",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Prenatal Prediction of Risk of the Fetal Hydantoin Syndrome

AU - Buehler, Bruce A.

AU - Delimont, Duane

AU - Van Waes, Michael

AU - Finnell, Richard H.

PY - 1990/5/31

Y1 - 1990/5/31

N2 - The well-known teratogenicity of several anticonvulsant medications is associated with an elevated level of oxidative metabolites that are normally eliminated by the enzyme epoxide hydrolase. In this study, we attempted to determine whether infants who are at risk for congenital malformations could be identified prenatally by the measurement of epoxide hydrolase activity. Before fetuses at risk could be identified, it was necessary to measure epoxide hydrolase activity in a randomly selected sample of amniocytes from 100 pregnant women. According to a thin-layer Chromatographic ssay, the randomly selected sample population had an apparently trimodal distribution, suggestive of an enzyme regulated by a single gene with two allelic forms. Fetuses homozygous for the recessive allele would have low epoxide hydrolase activity and would therefore be at risk if exposed to anticonvulsant drugs during gestation. In a prospective study of 19 pregnancies monitored by amniocentesis, an adverse outcome was predicted for four fetuses on the basis of low enzyme activity (<30 percent of the standard). In all four cases, the mother was receiving phenytoin monotherapy, and after birth the infants had clinical findings compatible with the fetal hydantoin syndrome. The 15 fetuses with enzyme activity above 30 percent of the standard were not considered to be at risk, and all 15 neonates lacked any characteristic features of the fetal hydantoin syndrome. These preliminary results suggest that this enzymatic biomarker may prove useful in determining which infants are at increased risk for congenital malformations induced by anticonvulsant drugs. THE association among maternal epilepsy, anticonvulsant drugs, and an increased incidence of congenital abnormalities has been suspected for at least 25 years.1 Despite numerous clinical and epidemiologic studies in humans that have documented well over 5000 births complicated by maternal epilepsy,2,3 only trimethadione,4 phenytoin,5,6 and valproic acid7 8 9 10 are widely considered to be human teratogens. Although all the commonly available anticonvulsant medications have at least been implicated as potential teratogens, recent attention has been focused on phenytoin, valproic acid, carbamazepine, and combination therapy with these three compounds.11 12 13 In terms of clinical understanding, the fetal hydantoin (phenytoin) syndrome is by far the…

AB - The well-known teratogenicity of several anticonvulsant medications is associated with an elevated level of oxidative metabolites that are normally eliminated by the enzyme epoxide hydrolase. In this study, we attempted to determine whether infants who are at risk for congenital malformations could be identified prenatally by the measurement of epoxide hydrolase activity. Before fetuses at risk could be identified, it was necessary to measure epoxide hydrolase activity in a randomly selected sample of amniocytes from 100 pregnant women. According to a thin-layer Chromatographic ssay, the randomly selected sample population had an apparently trimodal distribution, suggestive of an enzyme regulated by a single gene with two allelic forms. Fetuses homozygous for the recessive allele would have low epoxide hydrolase activity and would therefore be at risk if exposed to anticonvulsant drugs during gestation. In a prospective study of 19 pregnancies monitored by amniocentesis, an adverse outcome was predicted for four fetuses on the basis of low enzyme activity (<30 percent of the standard). In all four cases, the mother was receiving phenytoin monotherapy, and after birth the infants had clinical findings compatible with the fetal hydantoin syndrome. The 15 fetuses with enzyme activity above 30 percent of the standard were not considered to be at risk, and all 15 neonates lacked any characteristic features of the fetal hydantoin syndrome. These preliminary results suggest that this enzymatic biomarker may prove useful in determining which infants are at increased risk for congenital malformations induced by anticonvulsant drugs. THE association among maternal epilepsy, anticonvulsant drugs, and an increased incidence of congenital abnormalities has been suspected for at least 25 years.1 Despite numerous clinical and epidemiologic studies in humans that have documented well over 5000 births complicated by maternal epilepsy,2,3 only trimethadione,4 phenytoin,5,6 and valproic acid7 8 9 10 are widely considered to be human teratogens. Although all the commonly available anticonvulsant medications have at least been implicated as potential teratogens, recent attention has been focused on phenytoin, valproic acid, carbamazepine, and combination therapy with these three compounds.11 12 13 In terms of clinical understanding, the fetal hydantoin (phenytoin) syndrome is by far the…

UR - http://www.scopus.com/inward/record.url?scp=0025352429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025352429&partnerID=8YFLogxK

U2 - 10.1056/NEJM199005313222204

DO - 10.1056/NEJM199005313222204

M3 - Article

C2 - 2336087

AN - SCOPUS:0025352429

VL - 322

SP - 1567

EP - 1572

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -